<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00667654</url>
  </required_header>
  <id_info>
    <org_study_id>114-02P</org_study_id>
    <nct_id>NCT00667654</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of 4975 in the Treatment of Moderate to Severe Knee Pain Due to Osteoarthritis (OA)</brief_title>
  <official_title>A Phase 2, Open-label Study to Evaluate Safety and Tolerability, and to Explore the Efficacy, of Dosing Regimens of Intraarticular 4975 in Patients With Chronic Moderate to Severe Pain of the Knee Associated With Osteoarthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centrexion Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centrexion Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate dosing regimens of 4975 in terms of safety and tolerability when
      delivered as an intra-articular injection in the knee. Secondary objectives will be to
      explore the efficacy of 4975 in terms of onset, extent and duration of pain relief.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single site study. The study drug, 4975, will be administered in various dosing
      regimens by intra-articular injection followed by an observation period of up to 12 weeks.
      Pain in the treated knee will be assessed before, during and after administration of the
      study drug.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety of IA CNTX-4975 as measured by related AEs occurring on day of dosing measures of pain at prescribed times</measure>
    <time_frame>12 Weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate analgesic efficacy, as measured by the PGIC, following IA injection of CNTX-4975</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 12 in WOMAC subscale score</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">54</enrollment>
  <condition>Osteoarthritis of the Knee</condition>
  <arm_group>
    <arm_group_label>100-200 µg CNTX-4975</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>300-425 µg CNTX-4975</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose delivered as two separate lower doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>600-700 µg CNTX-4975</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose delivered as two separate lower doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>800 µg CNTX-4975</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose delivered as two separate lower doses</description>
  </arm_group>
  <arm_group>
    <arm_group_label>900-1000 µg CNTX-4975</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total dose delivered as two separate lower doses</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CNTX-4975</intervention_name>
    <description>Testing a range of dosing configurations to optimize patient tolerability</description>
    <arm_group_label>100-200 µg CNTX-4975</arm_group_label>
    <arm_group_label>300-425 µg CNTX-4975</arm_group_label>
    <arm_group_label>600-700 µg CNTX-4975</arm_group_label>
    <arm_group_label>800 µg CNTX-4975</arm_group_label>
    <arm_group_label>900-1000 µg CNTX-4975</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged 40 years or over.

          -  Body mass index (BMI) of 35 or less.

          -  History of OA of the knee for at least 1 year and has experienced pain in the target
             area for at least six months.

          -  X-Ray of the target knee.

          -  Willing and able to complete the study procedures.

        Exclusion Criteria:

          -  Female patients who are pregnant or lactating or who plan to get pregnant.

          -  Clinically significant form of joint disease other than OA.

          -  Medical condition that could adversely impact the patient's participation, safety or
             affect the conduct of the study.

          -  Prior major trauma in the target knee or major surgeries such as partial or total knee
             arthroplasty.

          -  Arthroscopic surgery on the target knee within 6 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William C Houghton, MD</last_name>
    <role>Study Director</role>
    <affiliation>Anesiva, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Shaun Comfort, MD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Anesiva, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Phamacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2008</study_first_submitted>
  <study_first_submitted_qc>April 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 28, 2008</study_first_posted>
  <disposition_first_submitted>October 11, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>October 11, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 12, 2016</disposition_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis, Knee</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

